New hope for myeloma patients: ELDORADO trial tests promising drug combo

NCT ID NCT07247097

First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 13 times

Summary

This study tests whether a new drug, elranatamab, combined with standard medications works better than the usual combination for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 160 adults will receive either elranatamab or daratumumab along with lenalidomide, bortezomib, and dexamethasone. The goal is to see which combination leads to fewer cancer cells remaining after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.